Researchers from the Abramson Cancer Center of the University of Pennsylvania described a death receptor pathway in cancer cells that has a primary role in its response to CAR-T cells.

A single leukemia cell inadvertently got mixed in with a batch of a patient’s immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported.